Publications

  1. Poduslo JF, Howell KG. Unique molecular signatures of Alzheimer's disease amyloid beta peptide mutations and deletion during aggregate/oligomer/fibril formation. J Neurosci Res. 2014 Nov 06.
    View PubMed
  2. Agyare EK, Jaruszewski KM, Curran GL, Rosenberg JT, Grant SC, Lowe VJ, Ramakrishnan S, Paravastu AK, Poduslo JF, Kandimalla KK. Engineering theranostic nanovehicles capable of targeting cerebrovascular amyloid deposits. J Control Release. 2014 Jul 10; 185:121-9. Epub 2014 Apr 13.
    View PubMed
  3. Marjanska M, Weigand SD, Preboske G, Wengenack TM, Chamberlain R, Curran GL, Poduslo JF, Garwood M, Kobayashi D, Lin JC, Jack CR Jr. Treatment effects in a transgenic mouse model of Alzheimer's disease: a magnetic resonance spectroscopy study after passive immunization. Neuroscience. 2014 Feb 14; 259:94-100. Epub 2013 Dec 04.
    View PubMed
  4. Jaruszewski KM, Curran GL, Swaminathan SK, Rosenberg JT, Grant SC, Ramakrishnan S, Lowe VJ, Poduslo JF, Kandimalla KK. Multimodal nanoprobes to target cerebrovascular amyloid in Alzheimer's disease brain. Biomaterials. 2014 Feb; 35(6):1967-76. Epub 2013 Dec 09.
    View PubMed
  5. Agyare EK, Leonard SR, Curran GL, Yu CC, Lowe VJ, Paravastu AK, Poduslo JF, Kandimalla KK. Traffic jam at the blood-brain barrier promotes greater accumulation of Alzheimer's disease amyloid-beta proteins in the cerebral vasculature. Mol Pharm. 2013 May 6; 10(5):1557-65. Epub 2013 Mar 05.
    View PubMed
  6. Poduslo JF, Howell KG, Olson NC, Ramirez-Alvarado M, Kandimalla KK. Alzheimer's disease amyloid beta-protein mutations and deletions that define neuronal binding/internalization as early stage nonfibrillar/fibrillar aggregates and late stage fibrils. Biochemistry. 2012 May 15; 51(19):3993-4003. Epub 2012 May 07.
    View PubMed
  7. Murphy MC, Curran GL, Glaser KJ, Rossman PJ, Huston J 3rd, Poduslo JF, Jack CR Jr, Felmlee JP, Ehman RL. Magnetic resonance elastography of the brain in a mouse model of Alzheimer's disease: initial results. Magn Reson Imaging. 2012 May; 30(4):535-9. Epub 2012 Feb 10.
    View PubMed
  8. Jaruszewski KM, Ramakrishnan S, Poduslo JF, Kandimalla KK. Chitosan enhances the stability and targeting of immuno-nanovehicles to cerebro-vascular deposits of Alzheimer's disease amyloid protein. Nanomedicine. 2012 Feb; 8(2):250-60. Epub 2011 Jun 24.
    View PubMed
  9. Trushina E, Nemutlu E, Zhang S, Christensen T, Camp J, Mesa J, Siddiqui A, Tamura Y, Sesaki H, Wengenack TM, Dzeja PP, Poduslo JF. Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer's disease. PLoS One. 2012; 7(2):e32737. Epub 2012 Feb 29.
    View PubMed
  10. Omtri RS, Davidson MW, Arumugam B, Poduslo JF, Kandimalla KK. Differences in the cellular uptake and intracellular itineraries of amyloid beta proteins 40 and 42: Ramifications for the Alzheimer's drug discovery. Molecular Pharmaceutics. 2012; 9(7):1887-97.
  11. Poduslo JF, Hultman KL, Curran GL, Preboske GM, Chamberlain R, Marjanska M, Garwood M, Jack CR Jr, Wengenack TM. Targeting vascular amyloid in arterioles of Alzheimer disease transgenic mice with amyloid beta protein antibody-coated nanoparticles. J Neuropathol Exp Neurol. 2011 Aug; 70(8):653-61.
    View PubMed
  12. Chamberlain R, Wengenack TM, Poduslo JF, Garwood M, Jack CR Jr. Magnetic resonance imaging of amyloid plaques in transgenic mouse models of Alzheimer's disease. Curr Med Imaging Rev. 2011 Feb; 7(1):3-7.
    View PubMed
  13. Wengenack TM, Reyes DA, Curran GL, Borowski BJ, Lin J, Preboske GM, Holasek SS, Gilles EJ, Chamberlain R, Marjanska M, Jack CR Jr, Garwood M, Poduslo JF. Regional differences in MRI detection of amyloid plaques in AD transgenic mouse brain. Neuroimage. 2011 Jan 1; 54(1):113-22. Epub 2010 Aug 20.
    View PubMed
  14. Sarkar G, Curran GL, Mahlum E, Decklever T, Wengenack TM, Blahnik A, Hoesley B, Lowe VJ, Poduslo JF, Jenkins RB. A carrier for non-covalent delivery of functional beta-galactosidase and antibodies against amyloid plaques and IgM to the brain. PLoS One. 2011; 6(12):e28881. Epub 2011 Dec 21.
    View PubMed
  15. Poduslo JF, Gilles EJ, Ramakrishnan M, Howell KG, Wengenack TM, Curran GL, Kandimalla KK. HH domain of Alzheimer's disease Abeta provides structural basis for neuronal binding in PC12 and mouse cortical/hippocampal neurons. PLoS One. 2010; 5(1):e8813. Epub 2010 Jan 21.
    View PubMed
  16. Ramakrishnan M, Kandimalla KK, Wengenack TM, Howell KG, Poduslo JF. Surface plasmon resonance binding kinetics of Alzheimer's disease amyloid beta peptide-capturing and plaque-binding monoclonal antibodies. Biochemistry. 2009 Nov 3; 48(43):10405-15.
    View PubMed
  17. Chamberlain R, Reyes D, Curran GL, Marjanska M, Wengenack TM, Poduslo JF, Garwood M, Jack CR Jr. Comparison of amyloid plaque contrast generated by T2-weighted, T2*-weighted, and susceptibility-weighted imaging methods in transgenic mouse models of Alzheimer's disease. Magn Reson Med. 2009 May; 61(5):1158-64.
    View PubMed
  18. Yao JK, Wengenack TM, Curran GL, Poduslo JF. Reduced membrane lipids in the cortex of Alzheimer's disease transgenic mice. Neurochem Res. 2009 Jan; 34(1):102-8. Epub 2008 Mar 29.
    View PubMed
  19. Kandimalla KK, Scott OG, Fulzele S, Davidson MW, Poduslo JF. Mechanism of neuronal versus endothelial cell uptake of Alzheimer's disease amyloid beta protein. PLoS One. 2009; 4(2):e4627. Epub 2009 Feb 27.
    View PubMed
  20. Agyare EK, Curran GL, Ramakrishnan M, Yu CC, Poduslo JF, Kandimalla KK. Development of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer's disease and cerebral amyloid angiopathy. Pharm Res. 2008 Nov; 25(11):2674-84. Epub 2008 Aug 20.
    View PubMed
  21. Ramakrishnan M, Wengenack TM, Kandimalla KK, Curran GL, Gilles EJ, Ramirez-Alvarado M, Lin J, Garwood M, Jack CR Jr, Poduslo JF. Selective contrast enhancement of individual Alzheimer's disease amyloid plaques using a polyamine and Gd-DOTA conjugated antibody fragment against fibrillar Abeta42 for magnetic resonance molecular imaging. Pharm Res. 2008 Aug; 25(8):1861-72. Epub 2008 Apr 29.
    View PubMed
  22. Wengenack TM, Jack CR Jr, Garwood M, Poduslo JF. MR microimaging of amyloid plaques in Alzheimer's disease transgenic mice. Eur J Nucl Med Mol Imaging. 2008 Mar; 35 Suppl 1:S82-8.
    View PubMed
  23. Kandimalla KK, Wengenack TM, Curran GL, Gilles EJ, Poduslo JF. Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice. J Pharmacol Exp Ther. 2007 Aug; 322(2):541-9. Epub 2007 May 15.
    View PubMed
  24. Poduslo JF, Ramakrishnan M, Holasek SS, Ramirez-Alvarado M, Kandimalla KK, Gilles EJ, Curran GL, Wengenack TM. In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques. J Neurochem. 2007 Jul; 102(2):420-33.
    View PubMed
  25. Hartman TK, Wengenack TM, Poduslo JF, van Deursen JM. Mutant mice with small amounts of BubR1 display accelerated age-related gliosis. Neurobiol Aging. 2007 Jun; 28(6):921-7. Epub 2006 Jun 15.
    View PubMed
  26. Jack CR Jr, Marjanska M, Wengenack TM, Reyes DA, Curran GL, Lin J, Preboske GM, Poduslo JF, Garwood M. Magnetic resonance imaging of Alzheimer's pathology in the brains of living transgenic mice: a new tool in Alzheimer's disease research. Neuroscientist. 2007 Feb; 13(1):38-48.
    View PubMed
  27. Kandimalla KK, Curran GL, Holasek SS, Gilles EJ, Wengenack TM, Ramirez-Alvarado M, Poduslo JF. Physiological and biophysical factors that influence Alzheimer's disease amyloid plaque targeting of native and putrescine modified human amyloid beta40. J Pharmacol Exp Ther. 2006 Jul; 318(1):17-25. Epub 2006 Mar 24.
    View PubMed
  28. Jack CR Jr, Wengenack TM, Reyes DA, Garwood M, Curran GL, Borowski BJ, Lin J, Preboske GM, Holasek SS, Adriany G, Poduslo JF. In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice. J Neurosci. 2005 Oct 26; 25(43):10041-8.
    View PubMed
  29. Marjanska M, Curran GL, Wengenack TM, Henry PG, Bliss RL, Poduslo JF, Jack CR, Ugurbil K, Garwood M. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc Natl Acad Sci U S A. 2005 Aug 16; 102(33):11906-10.
    View PubMed
  30. Kandimalla KK, Curran GL, Holasek SS, Gilles EJ, Wengenack TM, Poduslo JF. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation. J Pharmacol Exp Ther. 2005 Jun; 313(3):1370-8. Epub 2005 Mar 02.
    View PubMed
  31. Holasek SS, Wengenack TM, Kandimalla KK, Montano C, Gregor DM, Curran GL, Poduslo JF. Activation of the stress-activated MAP kinase, p38, but not JNK in cortical motor neurons during early presymptomatic stages of amyotrophic lateral sclerosis in transgenic mice. Brain Res. 2005 May 31; 1045(1-2):185-98. Epub 2005 Apr 25.
    View PubMed
  32. Jack CR Jr, Garwood M, Wengenack TM, Borowski B, Curran GL, Lin J, Adriany G, Grohn OH, Grimm R, Poduslo JF. In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn Reson Med. 2004 Dec; 52(6):1263-71.
    View PubMed
  33. Wengenack TM, Holasek SS, Montano CM, Gregor D, Curran GL, Poduslo JF. Activation of programmed cell death markers in ventral horn motor neurons during early presymptomatic stages of amyotrophic lateral sclerosis in a transgenic mouse model. Brain Res. 2004 Nov 19; 1027(1-2):73-86.
    View PubMed
  34. Poduslo JF, Curran GL, Peterson JA, McCormick DJ, Fauq AH, Khan MA, Wengenack TM. Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques. Biochemistry. 2004 May 25; 43(20):6064-75.
    View PubMed
  35. Poduslo JF, Wengenack TM, Curran GL, Wisniewski T, Sigurdsson EM, Macura SI, Borowski BJ, Jack CR Jr. Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis. 2002 Nov; 11(2):315-29.
    View PubMed
  36. Poduslo JF, Curran GL. Amyloid beta peptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood-brain barrier. Neuroreport. 2001 Oct 29; 12(15):3197-200.
    View PubMed
  37. Poduslo JF, Curran GL, Wengenack TM, Malester B, Duff K. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2001 Aug; 8(4):555-67.
    View PubMed
  38. Poduslo JF, Whelan SL, Curran GL, Wengenack TM. Therapeutic benefit of polyamine-modified catalase as a scavenger of hydrogen peroxide and nitric oxide in familial amyotrophic lateral sclerosis transgenics. Ann Neurol. 2000 Dec; 48(6):943-7.
    View PubMed
  39. Wengenack TM, Curran GL, Poduslo JF. Targeting alzheimer amyloid plaques in vivo. Nat Biotechnol. 2000 Aug; 18(8):868-72.
    View PubMed
  40. Burguera B, Couce ME, Curran GL, Jensen MD, Lloyd RV, Cleary MP, Poduslo JF. Obesity is associated with a decreased leptin transport across the blood-brain barrier in rats. Diabetes. 2000 Jul; 49(7):1219-23.
    View PubMed
  41. Wengenack TM, Whelan S, Curran GL, Duff KE, Poduslo JF. Quantitative histological analysis of amyloid deposition in Alzheimer's double transgenic mouse brain. Neuroscience. 2000; 101(4):939-44.
    View PubMed
  42. Reinholz MM, Merkle CM, Poduslo JF. Therapeutic benefits of putrescine-modified catalase in a transgenic mouse model of familial amyotrophic lateral sclerosis. Exp Neurol. 1999 Sep; 159(1):204-16.
    View PubMed
  43. Reinholz MM, Haggard JJ, Curran GL, Poduslo JF. Plasma pharmacokinetics, nervous system biodistribution and biostability, and spinal cord permeability at the blood-brain barrier of putrescine-modified catalase in the adult rat. Exp Neurol. 1999 Sep; 159(1):191-203.
    View PubMed
  44. Poduslo JF, Curran GL, Kumar A, Frangione B, Soto C. Beta-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma. J Neurobiol. 1999 Jun 5; 39(3):371-82.
    View PubMed
  45. Poduslo JF, Curran GL, Sanyal B, Selkoe DJ. Receptor-mediated transport of human amyloid beta-protein 1-40 and 1-42 at the blood-brain barrier. Neurobiol Dis. 1999 Jun; 6(3):190-9.
    View PubMed
  46. Poduslo JF, Curran GL, Gill JS. Putrescine-modified nerve growth factor: bioactivity, plasma pharmacokinetics, blood-brain/nerve barrier permeability, and nervous system biodistribution. J Neurochem. 1998 Oct; 71(4):1651-60.
    View PubMed
  47. Walikonis RS, Poduslo JF. Activity of cyclic AMP phosphodiesterases and adenylyl cyclase in peripheral nerve after crush and permanent transection injuries. J Biol Chem. 1998 Apr 10; 273(15):9070-7.
    View PubMed
  48. Wengenack TM, Curran GL, Olson EE, Poduslo JF. Putrescine-modified catalase with preserved enzymatic activity exhibits increased permeability at the blood-nerve and blood-brain barriers. Brain Res. 1997 Aug 29; 767(1):128-35.
    View PubMed
  49. Wengenack TM, Curran GL, Poduslo JF. Postischemic, systemic administration of polyamine-modified superoxide dismutase reduces hippocampal CA1 neurodegeneration in rat global cerebral ischemia. Brain Res. 1997 Apr 18; 754(1-2):46-54.
    View PubMed
  50. Poduslo JF, Curran GL, Haggard JJ, Biere AL, Selkoe DJ. Permeability and residual plasma volume of human, Dutch variant, and rat amyloid beta-protein 1-40 at the blood-brain barrier. Neurobiol Dis. 1997; 4(1):27-34.
    View PubMed
  51. Poduslo JF, Curran GL. Increased permeability of superoxide dismutase at the blood-nerve and blood-brain barriers with retained enzymatic activity after covalent modification with the naturally occurring polyamine, putrescine. J Neurochem. 1996 Aug; 67(2):734-41.
    View PubMed
  52. Poduslo JF, Curran GL. Polyamine modification increases the permeability of proteins at the blood-nerve and blood-brain barriers. J Neurochem. 1996 Apr; 66(4):1599-609.
    View PubMed
  53. Poduslo JF, Curran GL. Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res Mol Brain Res. 1996 Mar; 36(2):280-6.
    View PubMed
  54. Poduslo JF, Walikonis RS, Domec MC, Berg CT, Holtz-Heppelmann CJ. The second messenger, cyclic AMP, is not sufficient for myelin gene induction in the peripheral nervous system. J Neurochem. 1995 Jul; 65(1):149-59.
    View PubMed
  55. Poduslo JF, Curran GL, Berg CT. Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc Natl Acad Sci U S A. 1994 Jun 7; 91(12):5705-9.
    View PubMed
  56. Poduslo JF, Curran GL. Glycation increases the permeability of proteins across the blood-nerve and blood-brain barriers. Brain Res Mol Brain Res. 1994 Apr; 23(1-2):157-62.
    View PubMed
  57. Gupta SK, Pringle J, Poduslo JF, Mezei C. Induction of myelin genes during peripheral nerve remyelination requires a continuous signal from the ingrowing axon. J Neurosci Res. 1993 Jan; 34(1):14-23.
    View PubMed
  58. Low P, Kihara M, Cameron N, Cotter M, Poduslo J. Cause and effect of ischaemia in chronic experimental diabetic neuropathy. Diabet Med. 1993; 10 Suppl 2:52S-55S.
    View PubMed
  59. Podratz JL, Windebank AJ, Poduslo JF. Dialyzer associated neurotoxicity due to a change in fatty acid structure. Trans Am Soc Neurochem. 1993; 24:229.
  60. LeBlanc AC, Pringle J, Lemieux J, Poduslo JF, Mezei C. Regulation of 2',3'-cyclic nucleotide phosphodiesterase gene expression in experimental peripheral neuropathies. Brain Res Mol Brain Res. 1992 Sep; 15(1-2):40-6.
    View PubMed
  61. Poduslo JF, Curran GL. Increased permeability across the blood-nerve barrier of albumin glycated in vitro and in vivo from patients with diabetic polyneuropathy. Proc Natl Acad Sci U S A. 1992 Mar 15; 89(6):2218-22.
    View PubMed
  62. LeBlanc AC, Windebank AJ, Poduslo JF. P0 gene expression in Schwann cells is modulated by an increase of cAMP which is dependent on the presence of axons. Brain Res Mol Brain Res. 1992 Jan; 12(1-3):31-8.
    View PubMed
  63. Kihara M, Schmelzer JD, Poduslo JF, Curran GL, Nickander KK, Low PA. Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci U S A. 1991 Jul 15; 88(14):6107-11.
    View PubMed
  64. Gupta SK, Pringle J, Poduslo JF, Mezei C. Levels of proteolipid protein mRNAs in peripheral nerve are not under stringent axonal control. J Neurochem. 1991 May; 56(5):1754-62.
    View PubMed
  65. Yoshikawa H, Dyck PJ, Poduslo JF, Giannini C. Polyglucosan body axonal enlargement increases myelin spiral length but not lamellar number. J Neurol Sci. 1990 Aug; 98(1):107-17.
    View PubMed
  66. LeBlanc AC, Poduslo JF. Axonal modulation of myelin gene expression in the peripheral nerve. J Neurosci Res. 1990 Jul; 26(3):317-26.
    View PubMed
  67. Weerasuriya A, Curran GL, Poduslo JF. Development changes in blood-nerve transfer of albumin and endoneurial albumin content in rat sciatic nerve. Brain Res. 1990 Jun 25; 521:40-46.
    View PubMed
  68. Brunden KR, Windebank AJ, Poduslo JF. Role of axons in the regulation of P0 biosynthesis by Schwann cells. J Neurosci Res. 1990 Jun; 26(2):135-43.
    View PubMed
  69. Kohriyama T, Yu RK, Berg CT, Poduslo JF. Sulfate incorporation into peripheral nerve endoneurial glycolipids after crush and permanent transection injury. J Neurosci Res. 1990 Jun; 26(2):144-8.
    View PubMed
  70. Weerasuriya A, Curran GL, Poduslo JF. Physiological changes in the sciatic nerve endoneurium of lead-intoxicated rats: a model of endoneurial homeostasis. Brain Res. 1990 May 28; 517(1-2):1-6.
    View PubMed
  71. Poduslo JF. Golgi sulfation of the oligosaccharide chain of P0 occurs in the presence of myelin assembly but not in its absence. J Biol Chem. 1990 Mar 5; 265(7):3719-25.
    View PubMed
  72. Yao JK, Windebank AJ, Poduslo JF, Yoshino JE. Axonal regulation of Schwann cell glycolipid biosynthesis. Neurochem Res. 1990 Mar; 15(3):279-82.
    View PubMed
  73. LeBlanc AC, Poduslo JF. Regulation of apolipoprotein E gene expression after injury of the rat sciatic nerve. J Neurosci Res. 1990 Feb; 25(2):162-71.
    View PubMed
  74. Brunden KR, Windebank AJ, Poduslo JF. Catabolic regulation of the expression of the major myelin glycoprotein by Schwann cells in culture. J Neurochem. 1990 Feb; 54(2):459-66.
    View PubMed
  75. Gupta SK, Poduslo JF, Dunn R, Roder J, Mezei C. Myelin-associated glycoprotein gene expression in the presence and absence of Schwann cell-axonal contact. Dev Neurosci. 1990; 12(1):22-33.
    View PubMed
  76. Brunden KR, Poduslo JF. Posttranslational degradation of the major myelin glycoprotein by Schwann cells in vivo and in vitro. Ann N Y Acad Sci. 1990; 605:230-9.
    View PubMed
  77. Weerasuriya A, Curran GL, Poduslo JF. Blood-nerve transfer of albumin and its implications for the endoneurial microenvironment. Brain Res. 1989 Aug 7; 494(1):114-21.
    View PubMed
  78. Costantino-Ceccarini E, Poduslo JF. Regulation of UDP-galactose:ceramide galactosyltransferase and UDP-glucose:ceramide glucosyltransferase after crush and transection nerve injury. J Neurochem. 1989 Jul; 53(1):205-11.
    View PubMed
  79. Dyck PJ, Zimmerman BR, Vilen TH, Minnerath SR, Karnes JL, Yao JK, Poduslo JF. Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy. N Engl J Med. 1988 Sep 1; 319(9):542-8.
    View PubMed
  80. Gupta SK, Poduslo JF, Mezei C. Temporal changes in PO and MBP gene expression after crush-injury of the adult peripheral nerve. Brain Res. 1988 Sep; 464(2):133-41.
    View PubMed
  81. Poduslo JF, Curran GL, Dyck PJ. Increase in albumin, IgG, and IgM blood-nerve barrier indices in human diabetic neuropathy. Proc Natl Acad Sci U S A. 1988 Jul; 85(13):4879-83.
    View PubMed
  82. Poduslo JF, Curran GL, Brunden KR, Dyck PJ. IgM/IgG solid-phase antibody-capture assay with biotin/125I-streptavidin amplification: application to normal human sural nerve biopsies. J Neuroimmunol. 1988 May; 18(2):117-24.
    View PubMed
  83. Poduslo JF. Control of myelin gene expression by Schwann cells. Trans Am Soc Neurochem. 1988 Mar 6-11; 19:152.
  84. Yao JK, Poduslo JF. Biosynthesis of neutral glucocerebroside homologues in the absence of myelin assembly after nerve transection. J Neurochem. 1988 Feb; 50(2):630-8.
    View PubMed
  85. Low PA, Schmelzer JD, Ward KK, Curran GL, Poduslo JF. Effect of hyperbaric oxygenation on normal and chronic streptozotocin diabetic peripheral nerves. Exp Neurol. 1988 Jan; 99(1):201-12.
    View PubMed
  86. Brunden KR, Poduslo JF. A phorbol ester-sensitive kinase catalyzes the phosphorylation of P0 glycoprotein in myelin. J Neurochem. 1987 Dec; 49(6):1863-72.
    View PubMed
  87. Brunden KR, Berg CT, Poduslo JF. Isolation of an integral membrane glycoprotein by chloroform-methanol extraction and C3-reversed-phase high-performance liquid chromatography. Anal Biochem. 1987 Aug 1; 164(2):474-81.
    View PubMed
  88. LeBlanc AC, Poduslo JF, Mezei C. Gene expression in the presence or absence of myelin assembly. Brain Res. 1987 Apr; 388(1):57-67.
    View PubMed
  89. Brunden KR, Poduslo JF. Lysosomal delivery of the major myelin glycoprotein in the absence of myelin assembly: posttranslational regulation of the level of expression by Schwann cells. J Cell Biol. 1987 Mar; 104(3):661-9.
    View PubMed
  90. Windebank AJ, Poduslo JF. Neuronal growth factors produced by adult peripheral nerve after injury. Brain Res. 1986 Oct 15; 385(1):197-200.
    View PubMed
  91. Poduslo JF. Regulation of Schwann cell expression of myelin-specific glycoconjugates. Adv Biosci. 1986; 61:311-321.
  92. Ohi T, Poduslo JF, Dyck PJ. Increased endoneurial albumin in diabetic polyneuropathy. Neurology. 1985 Dec; 35(12):1790-1.
    View PubMed
  93. Ohi T, Poduslo JF, Curran GL, Dyck PJ. Quantitative method for detection of blood-nerve barrier alterations in experimental animal models of neuropathy. Exp Neurol. 1985 Nov; 90(2):365-72.
    View PubMed
  94. Poduslo JF, Windebank AJ. Differentiation-specific regulation of Schwann cell expression of the major myelin glycoprotein. Proc Natl Acad Sci U S A. 1985 Sep; 82(17):5987-91.
    View PubMed
  95. Poduslo JF, Yao JK. Association and release of the major intrinsic membrane glycoprotein from peripheral nerve myelin. Biochem J. 1985 May 15; 228(1):43-54.
    View PubMed
  96. Poduslo JF, Low PA, Nickander KK, Dyck PJ. Mammalian endoneurial fluid: collection and protein analysis from normal and crushed nerves. Brain Res. 1985 Apr 15; 332(1):91-102.
    View PubMed
  97. Poduslo JF. Posttranslational protein modification: biosynthetic control mechanisms in the glycosylation of the major myelin glycoprotein by Schwann cells. J Neurochem. 1985 Apr; 44(4):1194-206.
    View PubMed
  98. Poduslo JF, Dyck PJ, Berg CT. Regulation of myelination: Schwann cell transition from a myelin-maintaining state to a quiescent state after permanent nerve transection. J Neurochem. 1985 Feb; 44(2):388-400.
    View PubMed
  99. Poduslo JF, Berg CT, Ross SM, Spencer PS. Regulation of myelination: axons not required for the biosynthesis of basal levels of the major myelin glycoprotein by Schwann cells in denervated distal segments of the adult cat sciatic nerve. J Neurosci Res. 1985; 14(2):177-85.
    View PubMed
  100. Poduslo JF, Berg CT, Dyck PJ. Schwann cell expression of a major myelin glycoprotein in the absence of myelin assembly. Proc Natl Acad Sci U S A. 1984 Mar; 81(6):1864-6.
    View PubMed
  101. Kishishita M, Luka J, Vroman B, Poduslo JF, Pearson GR. Production of monoclonal antibody to a late intracellular Epstein-Barr virus-induced antigen. Virology. 1984 Mar; 133(2):363-75.
    View PubMed
  102. Poduslo JF. Regulation of myelination: biosynthesis of the major myelin glycoprotein by Schwann cells in the presence and absence of myelin assembly. J Neurochem. 1984 Feb; 42(2):493-503.
    View PubMed
  103. Poduslo JF, Low PA, Windebank AJ, Dyck PJ, Berg CT, Schmelzer JD. Altered blood-nerve barrier in experimental lead neuropathy assessed by changes in endoneurial albumin concentration. J Neurosci. 1982 Oct; 2(10):1507-14.
    View PubMed
  104. Low PA, Yao JK, Poduslo JF, Donald DE, Dyck PJ. Peripheral nerve microenvironment: collection of endoneurially enriched fluid. Exp Neurol. 1982 Jul; 77(1):208-14.
    View PubMed
  105. Poduslo JF. Developmental regulation of the carbohydrate composition of glycoproteins associated with central nervous system myelin. J Neurochem. 1981 Jun; 36(6):1924-31.
    View PubMed
  106. Reigner J, Matthieu JM, Kraus-Ruppert R, Lassmann H, Poduslo JF. Myelin proteins, glycoproteins, and myelin-released enzymes in experimental demyelination of the rabbit optic nerve: sequence of events. J Neurochem. 1981; 36:1986-1995.
    View PubMed
  107. Poduslo JF. Glycoprotein molecular weight estimation using SDS-pore gradient electrophoresis: comparison of tris-glycine and tris-borate-EDTA buffer systems. Ann Biochem. 1981; 114:131-139.
  108. Poduslo JF, Harman JL, McFarlin DE. Lectin receptors in central nervous system myelin. J Neurochem. 1980 Jun; 34(6):1733-44.
    View PubMed
  109. Poduslo JF, Rodbard D. Estimation using sodium dodecyl sulfate-pore gradient electrophoresis. Anal Biochem. 1980; 101:394-406.
    View PubMed
  110. Poduslo JF, McFarlin DE. Immunogenicity of a membrane surface glycoprotein associated with central nervous system myelin. Brain Res. 1978 Dec 22; 159(1):234-8.
    View PubMed
  111. Poduslo JF. The molecular architecture of myelin: identification of the external surface membrane components. Adv Exp Med Biol. 1978; 100:189-205.
    View PubMed
  112. Poduslo JF, Everly JL, Quarles RH. A low molecular weight glycoprotein associated with isolated myelin: distinction from myelin proteolipid protein. J Neurochem. 1977 May; 28(5):977-86.
    View PubMed
  113. Poduslo JF, Quarles RH, Brady RO. External labeling of galactose in surface membrane glycoproteins of the intact myelin sheath. J Biol Chem. 1976 Jan 10; 251(1):153-8.
    View PubMed
  114. Matthieu JM, Quarles RH, Poduslo JF, Brady RO. 35S-sulfate incorporation into myelin glycoproteins I. Central nervous system. Biochim Biophys Acta. 1975; 392:159-166.
    View PubMed
  115. Poduslo JF, Braun PE. Topographical arrangement of membrane proteins in the intact myelin sheath. J Biol Chem. 1975; 250:1099-1105.
    View PubMed
  116. Poduslo JF, Greenberg CS, Glick MC. Proteins exposed on the surface of mammalian membranes. Biochemistry. 1972 Jul 4; 11(14):2616-21.
    View PubMed
  117. Suzuki K, Poduslo JF, Poduslo SE. Further evidence for a specific ganglioside fraction closely associated with myelin. Biochim Biophys Acta. 1968 May 1; 152(3):576-86.
    View PubMed